Phase 1 RCC Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Phase 1Phase 2
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting
Phase 1Phase 2
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Advanced Clear Cell Renal Carcinoma (Ccrcc)Papillary Renal Cell Carcinoma (Prcc)
National Cancer Institute (NCI)100 enrolled1 locationNCT05665361
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb234 enrolled72 locationsNCT07293351
Recruiting
Phase 1Phase 2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled7 locationsNCT07300241
Recruiting
Phase 1
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Breast Cancer MetastaticNeuroendocrine TumorsRenal Cell Carcinoma (RCC)+2 more
SAPU NANO (US) LLC27 enrolled1 locationNCT07369505
Recruiting
Phase 1Phase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 1
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Ovarian CancerCervical CancerLung Cancer+3 more
Chongqing Precision Biotech Co., Ltd90 enrolled1 locationNCT07181720
Recruiting
Phase 1Phase 2
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Advanced Solid Tumor+3 more
GI Innovation, Inc.76 enrolled3 locationsNCT07172802
Recruiting
Phase 1
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Pancreas CancerSolid Tumor CancerHCC - Hepatocellular Carcinoma+6 more
LaunXP Biomedical Co., Ltd.24 enrolled2 locationsNCT06883539
Recruiting
Phase 1
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
HNSCCSolid TumorCRC+1 more
SparX Biotech(Jiangsu) Co., Ltd.232 enrolled4 locationsNCT06259552